RÉSUMÉ
Deposition of amyloid-ß (Aß) in the brain can impair neuronal function and contribute to cognitive decline in Alzheimer's disease (AD). Here, we found that dopamine and the dopamine precursor levodopa (also called l-DOPA) induced Aß degradation in the brain. Chemogenetic approaches in mice revealed that the activation of dopamine release from ventral tegmental area (VTA) neurons increased the abundance and activity of the Aß-degrading enzyme neprilysin and reduced the amount of Aß deposits in the prefrontal cortex in a neprilysin-dependent manner. Aged mice had less dopamine and neprilysin in the anterior cortex, a decrease that was accentuated in AD model mice. Treating AD model mice with levodopa reduced Aß deposition and improved cognitive function. These observations demonstrate that dopamine promotes brain region-specific, neprilysin-dependent degradation of Aß, suggesting that dopamine-associated strategies have the potential to treat this aspect of AD pathology.
Sujet(s)
Maladie d'Alzheimer , Peptides bêta-amyloïdes , Dopamine , Néprilysine , Aire tegmentale ventrale , Néprilysine/métabolisme , Néprilysine/génétique , Animaux , Dopamine/métabolisme , Peptides bêta-amyloïdes/métabolisme , Maladie d'Alzheimer/métabolisme , Maladie d'Alzheimer/anatomopathologie , Souris , Aire tegmentale ventrale/métabolisme , Aire tegmentale ventrale/effets des médicaments et des substances chimiques , Lévodopa/pharmacologie , Encéphale/métabolisme , Souris transgéniques , Modèles animaux de maladie humaine , Humains , Protéolyse/effets des médicaments et des substances chimiques , Souris de lignée C57BL , Cortex préfrontal/métabolisme , MâleRÉSUMÉ
While many studies focus on segmental variation in Parkinsonian speech, little is known about prosodic modulations reflecting the ability to adapt to communicative demands in people with Parkinson's disease (PwPD). This type of prosodic modulation is important for social interaction, and it involves modifications in speech melody (intonational level) and articulation of consonants and vowels (segmental level). The present study investigates phonetic cues of prosodic modulations with respect to different focus structures in mild dysarthric PwPD as a function of levodopa. Acoustic and kinematic speech parameters of 25 PwPD were assessed in two motor conditions. Speech production data from PwPD were collected before (medication-OFF) and after levodopa intake (medication-ON) by means of 3-D electromagnetic articulography. On the acoustic level, intensity, pitch, and syllable durations were analyzed. On the kinematic level, movement duration and amplitude were investigated. Spatio-temporal modulations of speech parameters were examined and compared across three different prosodic focus structures (out-of-focus, broad focus, contrastive focus) to display varying speech demands. Overall, levodopa had beneficial effects on motor performance, speech loudness, and pitch modulation. Acoustic syllable durations and kinematic movement durations did not change, revealing no systematic effects of motor status on the temporal domain. In contrast, there were spatial modulations of the oral articulators: tongue tip movements were smaller and lower lip movements were larger in amplitude under levodopa, reflecting a more agile and efficient articulatory movement under levodopa. Thus, respiratory-phonatory functions and consonant production improved, while syllable duration and tongue body kinematics did not change. Interestingly, prominence marking strategies were comparable between the medication conditions under investigation, and in fact, appear to be preserved in mild dysarthric PwPD.
Sujet(s)
Lévodopa , Maladie de Parkinson , Humains , Maladie de Parkinson/physiopathologie , Maladie de Parkinson/traitement médicamenteux , Mâle , Femelle , Sujet âgé , Adulte d'âge moyen , Lévodopa/usage thérapeutique , Lévodopa/administration et posologie , Lévodopa/pharmacologie , Parole/physiologie , Acoustique de la voix , Phénomènes biomécaniques , Phonétique , Dysarthrie/physiopathologie , Dysarthrie/étiologieRÉSUMÉ
Parkinson's disease (PD) is a chronic neurodegenerative case. As the disease progresses, the response time to doses of levodopa (L-Dopa) becomes shorter and the effects of the drug are severely limited by some undesirable side effects such as the 'on-off' phenomenon. In several diseases, including Parkinson's, nanoparticles can deliver antioxidant compounds that reduce oxidative stress. This study evaluates and compares the neuroprotective effects of L-Dopa-modified zinc nanoparticles (ZnNPs) in the 6-hydroxydopamine (6-OHDA)-induced PD rat model. For this purpose, the synthesis of NPs was carried out. Scanning electron microscopy, X-ray diffraction and Fourier transform infrared spectrophotometer were used for characterization. The rats were randomized into 9 experimental groups: control, lesion group (6-OHDA), 6-OHDA + 5 mg/kg L-Dopa, 6-OHDA + 10 mg/kg L-Dopa, 6-OHDA + 20 mg/kg L-Dopa, 6-OHDA + 20 mg/kg ZnNPs, 6-OHDA + 40 mg/kg ZnNPs, 6-OHDA + 30 mg/kg ZnNPs + L-Dopa, and 6-OHDA + 60 mg/kg ZnNPs + L-Dopa. Behavioral tests were performed on all groups 14 days after treatment. Phosphatase and tensin homolog, Excitatory amino acid transporter 1/2, and Glutamine synthetase gene analyses were performed on brain samples taken immediately after the tests. In addition, histological and immunohistochemical methods were used to determine the general structure and properties of the tissues. We obtained important findings that L-Dopa-modified ZnNPs increased the activity of glutamate transporters. Our experiment showed that glutamate increases neuronal cell vitality and improves behavioral performance. Therefore, L-Dopa-modified ZnNPs can be used to prevent neurotoxicity. According to what we found, results show that L-Dopa-modified ZnNPs will lend to the effective avoidance and therapy of PD.
Sujet(s)
Modèles animaux de maladie humaine , Lévodopa , Neuroprotecteurs , Oxidopamine , Oxyde de zinc , Animaux , Lévodopa/pharmacologie , Rats , Neuroprotecteurs/pharmacologie , Oxyde de zinc/composition chimique , Oxyde de zinc/pharmacologie , Mâle , Maladie de Parkinson/traitement médicamenteux , Maladie de Parkinson/métabolisme , Nanoparticules métalliques/composition chimique , Nanoparticules/composition chimique , Syndrome parkinsonien secondaire/induit chimiquement , Syndrome parkinsonien secondaire/traitement médicamenteux , Syndrome parkinsonien secondaire/anatomopathologie , Syndrome parkinsonien secondaire/métabolisme , Stress oxydatif/effets des médicaments et des substances chimiques , Rat WistarRÉSUMÉ
Alterations of the microbiota-gut-brain axis has been associated with intestinal and neuronal inflammation in Parkinson's disease (PD). The aim of this work was to study some mechanisms associated with the neuroprotective effect of a combination (MIX) of lactic acid bacteria (LAB) composed by Lactiplantibacillus plantarum CRL2130 (riboflavin overproducing strain), Streptococcus thermophilus CRL808 (folate producer strain), and CRL807 (immunomodulatory strain) in cell cultures and in a chronic model of parkinsonism induced with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in aged mice, and under levodopa-benserazide treatment. In vitro, N2a differentiated neurons were exposed to the neurotoxin 1-methyl-4-phenylpyridinium (MPP+) and treated with intracellular bacterial extracts or with conditioned media from BV-2 cells exposed to the bacterial extracts. In vivo, motor skills, tyrosine hydrolase (TH) in brain and cytokine concentrations in serum and in brain were evaluated. The study of the faecal microbiota and the histology of the small intestine was also performed. The results showed that the neuroprotective effect associated with LAB MIX administration did not interfere with levodopa-benserazide treatment. This effect could be associated with the antioxidant and immunomodulatory potential of the LAB selected in the MIX, and was associated with the significant improvement in the motor tests and a higher number of TH + cells in the brain. In addition, LAB MIX administration was associated with modulation of the immune response. LAB administration decreased intestinal damage with an increase in the villus length /crypt depth ratio. Finally, the administration of the LAB MIX in combination with levodopa-benserazide treatment was able to partially revert the intestinal dysbiosis observed in the model, showing greater similarity to the profiles of healthy controls, and highlighting the increase in the Lactobacillaceae family. Different mechanisms of action would be related to the protective effect of the selected LAB combination which has the potential to be evaluated as an adjuvant for conventional PD therapies.
Sujet(s)
Bensérazide , Lévodopa , Souris de lignée C57BL , Neuroprotecteurs , Syndromes parkinsoniens , Animaux , Lévodopa/pharmacologie , Bensérazide/pharmacologie , Bensérazide/usage thérapeutique , Neuroprotecteurs/usage thérapeutique , Neuroprotecteurs/pharmacologie , Syndromes parkinsoniens/traitement médicamenteux , Syndromes parkinsoniens/métabolisme , Mâle , Souris , Association médicamenteuse , Microbiome gastro-intestinal/effets des médicaments et des substances chimiques , Modèles animaux de maladie humaine , Lactobacillales , Probiotiques/usage thérapeutique , Antiparkinsoniens/pharmacologie , Antiparkinsoniens/usage thérapeutique , Streptococcus thermophilus/effets des médicaments et des substances chimiquesRÉSUMÉ
Dopamine (DA) D2 receptors (D2Rs) have 2 isoforms, a long form (D2L) and a short form (D2S). D2L is predominantly postsynaptic in the striatal medium spiny neurons and cholinergic interneurons. D2S is principally presynaptic autoreceptors in the nigrostriatal DA neurons. Recently, we demonstrated that L-3,4-dihydroxyphenylalanine (L-DOPA) augments D2L function through the coupling between D2L and GPR143, a receptor of L-DOPA that was originally identified as the gene product of ocular albinism 1. Here we show that GPR143 modifies the functions of D2L and D2S in an opposite manner. Haloperidol-induced catalepsy was attenuated in DA neuron-specific Gpr143 gene-deficient (Dat-cre;Gpr143flox/y) mice, compared with wild-type (Wt) mice. Haloperidol increased in vivo DA release from the dorsolateral striatum, and this increase was augmented in Gpr143-/y mice compared with Wt mice. A D2R agonist quinpirole-induced increase in the phosphorylation of GSK3ß(pGSK3ß(S9)) was enhanced in Chinese hamster ovary (CHO) cells coexpressing D2L and GPR143 compared with cells expressing D2L alone, while it was suppressed in cells coexpressing D2S and GPR143 compared with D2S alone, suggesting that GPR143 differentially modifies D2R functions depending on its isoforms of D2L and D2S.
Sujet(s)
Cricetulus , Dopamine , Halopéridol , Récepteur D2 de la dopamine , Animaux , Récepteur D2 de la dopamine/métabolisme , Récepteur D2 de la dopamine/génétique , Halopéridol/pharmacologie , Cellules CHO , Dopamine/métabolisme , Corps strié/métabolisme , Mâle , Glycoprotéines membranaires/métabolisme , Glycoprotéines membranaires/génétique , Isoformes de protéines/métabolisme , Isoformes de protéines/génétique , Souris , Lévodopa/pharmacologie , Catalepsie/induit chimiquement , Catalepsie/génétique , Catalepsie/métabolisme , Souris de lignée C57BL , Phosphorylation , Récepteurs couplés aux protéines G/métabolisme , Récepteurs couplés aux protéines G/génétique , Récepteurs couplés aux protéines G/physiologie , Quinpirole/pharmacologie , Neurones dopaminergiques/métabolisme , Glycogen synthase kinase 3 beta/métabolismeRÉSUMÉ
Psychotic symptoms and delusional beliefs have been linked to dopamine transmission in both healthy and clinical samples and are assumed to result at least in part from perceiving illusory patterns in noise. However, the existing literature on the role of dopamine in detecting patterns in noise is inconclusive. To address this issue, we assessed the effect of manipulating dopaminergic neurotransmission on illusory pattern perception in healthy individuals (n = 48, n = 19 female) in a double-blind placebo-controlled within-subjects design (see preregistration at https://osf.io/a4k9j/). We predicted individuals on versus off Ê-DOPA to be more likely to perceive illusory patterns, specifically objects in images containing only noise. Using a signal detection model, however, we found no credible evidence that Ê-DOPA compared with placebo increased false alarm rates. Further, Ê-DOPA did not reliably modulate measures of accuracy, discrimination sensitivity, and response bias. In all cases, Bayesian statistics revealed strong evidence in favor of the null hypothesis. The task design followed previous work on illusory pattern perception and comprised a limited number of items per condition. The results therefore need to be interpreted with caution, as power was limited. Future studies should address illusory pattern perception using more items and take into account potential dose-dependent effects and differential effects in healthy versus clinical samples.
Sujet(s)
Dopamine , Illusions , Lévodopa , Humains , Femelle , Mâle , Méthode en double aveugle , Adulte , Illusions/physiologie , Illusions/effets des médicaments et des substances chimiques , Dopamine/métabolisme , Jeune adulte , Lévodopa/pharmacologie , Lévodopa/administration et posologie , Transmission synaptique/effets des médicaments et des substances chimiques , Transmission synaptique/physiologie , Agents dopaminergiques/pharmacologie , Reconnaissance visuelle des formes/physiologie , Reconnaissance visuelle des formes/effets des médicaments et des substances chimiques , Théorème de BayesRÉSUMÉ
Brain organoids are being recognized as valuable tools for drug evaluation in neurodegenerative diseases due to their similarity to the human brain's structure and function. However, a critical challenge is the lack of selective and sensitive electrochemical sensing platforms to detect the response of brain organoids, particularly changes in the neurotransmitter concentration upon drug treatment. This study introduces a 3D concave electrode patterned with a mesoporous Au nanodot for the detection of electrochemical signals of dopamine in response to drugs in brain organoids for the first time. The mesoporous Au nanodot-patterned film was fabricated using laser interference lithography and electrochemical deposition. Then, the film was attached to a polymer-based 3D concave mold to obtain a 3D concave electrode. Midbrain organoids generated from Parkinson's disease (PD) patient-derived iPSCs with gene mutations (named as PD midbrain organoid) or normal midbrain organoids were positioned on the developed 3D concave electrode. The 3D concave electrode showed a 1.4 times higher electrochemical signal of dopamine compared to the bare gold electrode. And the dopamine secreted from normal midbrain organoids or PD midbrain organoids on the 3D concave electrode could be detected electrochemically. After the treatment of PD midbrain organoids with levodopa, the drug for PD, the increase in dopamine level was detected due to the activation of dopaminergic neurons by the drug. The results suggest the potential of the proposed 3D concave electrode combined with brain organoids as a useful tool for assessing drug efficacy. This sensing system can be applied to a variety of organoids for a comprehensive drug evaluation.
Sujet(s)
Dopamine , Électrodes , Or , Mésencéphale , Organoïdes , Maladie de Parkinson , Humains , Maladie de Parkinson/traitement médicamenteux , Maladie de Parkinson/anatomopathologie , Organoïdes/anatomopathologie , Or/composition chimique , Mésencéphale/cytologie , Dopamine/analyse , Porosité , Lévodopa/pharmacologie , Techniques électrochimiques/méthodes , Techniques électrochimiques/instrumentation , Évaluation préclinique de médicament , Nanoparticules métalliques/composition chimiqueRÉSUMÉ
The striatum integrates dopaminergic and glutamatergic inputs to select preferred versus alternative actions. However, the precise mechanisms underlying this process remain unclear. One way to study action selection is to understand how it breaks down in pathological states. Here, we explored the cellular and synaptic mechanisms of levodopa-induced dyskinesia (LID), a complication of Parkinson's disease therapy characterized by involuntary movements. We used an activity-dependent tool (FosTRAP) in conjunction with a mouse model of LID to investigate functionally distinct subsets of striatal direct pathway medium spiny neurons (dMSNs). In vivo, levodopa differentially activates dyskinesia-associated (TRAPed) dMSNs compared to other dMSNs. We found this differential activation of TRAPed dMSNs is likely to be driven by higher dopamine receptor expression, dopamine-dependent excitability, and excitatory input from the motor cortex and thalamus. Together, these findings suggest how the intrinsic and synaptic properties of heterogeneous dMSN subpopulations integrate to support action selection.
Sujet(s)
Corps strié , Dopamine , Lévodopa , Neurones , Animaux , Dopamine/métabolisme , Lévodopa/pharmacologie , Souris , Corps strié/métabolisme , Corps strié/anatomopathologie , Neurones/métabolisme , Dyskinésie due aux médicaments/métabolisme , Dyskinésie due aux médicaments/anatomopathologie , Synapses/métabolisme , Mâle , Souris de lignée C57BL , Potentiels d'action/effets des médicaments et des substances chimiquesRÉSUMÉ
The gene product of ocular albinism 1 (OA1)/G-protein-coupled receptor (GPR)143 is a receptor for L-3,4-dihydroxyphenylanine (l-DOPA), the most effective agent for Parkinson's disease. When overexpressed, human wild-type GPR143, but not its mutants, inhibits neurite outgrowth in PC12 cells. We investigated the downstream signaling pathway for GPR143-induced inhibition of neurite outgrowth. Nifedipine restored GPR143-induced neurite outgrowth inhibition to the level of control transfectant but did not affect outgrowth in GPR143-knockdown cells. Cilnidipine and flunarizine also suppressed the GPR143-induced inhibition, but their effects at higher concentrations still occurred even in GPR143-knockdown cells. These results suggest that GPR143 regulates neurite outgrowth via L-type calcium channel(s).
Sujet(s)
Canaux calciques de type L , Excroissance neuronale , Nifédipine , Récepteurs couplés aux protéines G , Cellules PC12 , Animaux , Rats , Canaux calciques de type L/métabolisme , Canaux calciques de type L/génétique , Nifédipine/pharmacologie , Excroissance neuronale/effets des médicaments et des substances chimiques , Récepteurs couplés aux protéines G/métabolisme , Récepteurs couplés aux protéines G/génétique , Récepteurs couplés aux protéines G/physiologie , Humains , Protéines de l'oeil/génétique , Protéines de l'oeil/métabolisme , Protéines de l'oeil/pharmacologie , Flunarizine/pharmacologie , Transduction du signal/effets des médicaments et des substances chimiques , Lévodopa/pharmacologie , Techniques de knock-down de gènes , Neurites/effets des médicaments et des substances chimiques , Inhibiteurs des canaux calciques/pharmacologie , Glycoprotéines membranairesRÉSUMÉ
Parkinson's is a progressive neurodegenerative disease of the nervous system. It has no cure, but its symptoms can be managed by supplying dopamine artificially to the brain.This work aims to engineer tricompartmental polymeric microcarriers by electrohydrodynamic cojetting technique to encapsulate three PD (Parkinson's disease) drugs incorporated with high encapsulation efficiency (â¼100%) in a single carrier at a fixed drug ratio of 4:1:8 (Levodopa (LD): Carbidopa(CD): Entacapone (ENT)). Upon oral administration, the drug ratio needs to be maintained during subsequent release from microparticles to enhance the bioavailability of primary drug LD. This presents a notable challenge, as the three drugs vary in their aqueous solubility (LD > CD > ENT). The equilibrium of therapeutic release was achieved using a combination of FDA-approved polymers (PLA, PLGA, PCL, and PEG) and the disc shape of particles. In vitro studies demonstrated the simultaneous release of all the three therapeutics in a sustained and controlled manner. Additionally, pharmacodynamics and pharmacokinetics studies in Parkinson's disease rats induced by rotenone showed a remarkable improvement in PD conditions for the microparticles-fed rats, thereby showing a great promise toward efficient management of PD.
Sujet(s)
Carbidopa , Catéchols , Préparations à action retardée , Vecteurs de médicaments , Lévodopa , Maladie de Parkinson , Carbidopa/pharmacocinétique , Carbidopa/administration et posologie , Carbidopa/usage thérapeutique , Carbidopa/pharmacologie , Animaux , Lévodopa/pharmacocinétique , Lévodopa/administration et posologie , Lévodopa/usage thérapeutique , Lévodopa/pharmacologie , Maladie de Parkinson/traitement médicamenteux , Préparations à action retardée/composition chimique , Catéchols/composition chimique , Catéchols/usage thérapeutique , Catéchols/pharmacologie , Catéchols/pharmacocinétique , Vecteurs de médicaments/composition chimique , Rats , Mâle , Nitriles/pharmacocinétique , Nitriles/usage thérapeutique , Nitriles/pharmacologie , Antiparkinsoniens/pharmacocinétique , Antiparkinsoniens/usage thérapeutique , Antiparkinsoniens/administration et posologie , Antiparkinsoniens/pharmacologie , Libération de médicament , Rat Sprague-Dawley , Roténone/pharmacologieRÉSUMÉ
The loss of midbrain dopaminergic (DA) neurons is the fundamental pathological feature of Parkinson's disease (PD). PD causes chronic pain in two-thirds of patients. Recent studies showed that the activation of the pedunculopontine tegmental nucleus (PPTg) can effectively relieve inflammatory pain and neuropathic pain. The PPTg is located in the pontomesencephalic tegmentum, a target of deep brain stimulation (DBS) treatment in PD, and is involved in motor control and sensory integration. To test whether the lesion of midbrain DA neurons induced pain hypersensitivity, and whether the chemogenetic activation of the PPTg could modulate the pain, the AAV-hM3Dq receptor was transfected and expressed into the PPTg neurons of 6-hydroxydopamine-lesioned mice. In this study, von Frey, open field, and adhesive tape removal tests were used to assess animals' pain sensitivity, locomotor activity, and sensorimotor function and somatosensory perception, respectively. Here, we found that the lesion of midbrain DA neurons induced a minor deficit in voluntary movement but did not affect sensorimotor function and somatosensory perception in the tape removal test. The results showed that lesion led to pain hypersensitivity, which could be alleviated both by levodopa and by the chemogenetic activation of the PPTg. Activating the PPTg may be a potential therapeutic strategy to relieve pain phenotypes in PD.
Sujet(s)
Neurones dopaminergiques , Mésencéphale , Noyau tegmental pédonculopontin , Animaux , Noyau tegmental pédonculopontin/métabolisme , Neurones dopaminergiques/métabolisme , Souris , Mésencéphale/métabolisme , Mâle , Maladie de Parkinson/thérapie , Maladie de Parkinson/physiopathologie , Douleur/étiologie , Douleur/métabolisme , Souris de lignée C57BL , Stimulation cérébrale profonde/méthodes , Modèles animaux de maladie humaine , Lévodopa/pharmacologie , OxidopamineRÉSUMÉ
This study presents the effects of treating polystyrene (PS) cell culture plastic with oxidoreductase enzyme laccase and the catechol substrates caffeic acid (CA), L-DOPA, and dopamine on the culturing of normal human epidermal melanocytes (NHEMs) and human embryonal carcinoma cells (NTERA-2). The laccase-substrate treatment improved PS hydrophilicity and roughness, increasing NHEM and NTERA-2 adherence, proliferation, and NHEM melanogenesis to a level comparable with conventional plasma treatment. Cell adherence dynamics and proliferation were evaluated. The NHEM endpoint function was quantified by measuring melanin content. PS surfaces treated with laccase and its substrates demonstrated the forming of polymer-like structures. The surface texture roughness gradient and the peak curvature were higher on PS treated with a combination of laccase and substrates than laccase alone. The number of adherent NHEM and NTERA-2 was significantly higher than on the untreated surface. The proliferation of NHEM and NTERA-2 correspondingly increased on treated surfaces. NHEM melanin content was enhanced 6-10-fold on treated surfaces. In summary, laccase- and laccase-substrate-modified PS possess improved PS surface chemistry/hydrophilicity and altered roughness compared to untreated and plasma-treated surfaces, facilitating cellular adherence, subsequent proliferation, and exertion of the melanotic phenotype. The presented technology is easy to apply and creates a promising custom-made, substrate-based, cell-type-specific platform for both 2D and 3D cell culture.
Sujet(s)
Acides caféiques , Prolifération cellulaire , Dopamine , Laccase , Mélanines , Mélanocytes , Polystyrènes , Humains , Laccase/métabolisme , Mélanocytes/métabolisme , Mélanocytes/effets des médicaments et des substances chimiques , Prolifération cellulaire/effets des médicaments et des substances chimiques , Polystyrènes/composition chimique , Acides caféiques/pharmacologie , Acides caféiques/composition chimique , Dopamine/métabolisme , Mélanines/métabolisme , Adhérence cellulaire/effets des médicaments et des substances chimiques , Lévodopa/pharmacologie , Lévodopa/métabolisme , Lévodopa/composition chimique , Propriétés de surface , Lignée cellulaire tumorale , Cellules souches de carcinome embryonnaire/métabolisme , Cellules souches de carcinome embryonnaire/effets des médicaments et des substances chimiquesRÉSUMÉ
Background: Parkinson's disease (PD) is characterized by striatal dopamine deficiency. Since dopamine cannot cross the digestive and blood-brain barriers, its precursor, levodopa (L-DOPA), remains the mainstay of treatment. However, the significant pharmacokinetic (Pk) and pharmacodynamic (Pd) limitations of L-DOPA, combined with the severity of PD, may trigger motor and non-motor complications, for which continuous dopaminergic delivery therapies have been developed. Objective: The aim of this study was to review the literature on the Pk/Pd limitations of L-DOPA and how current treatments of continuous dopaminergic administration ameliorate these problems, in order to identify the need for new therapeutic avenues. Methods: A comprehensive literature search was carried out using PubMed and 75 articles were initially extracted. Following independent screening by two reviewers and consideration of eligibility, 10 articles were chosen for further analysis. Information concerning the Pk/Pd of L-DOPA was classified for each article. Results: Pk/Pd problems notably include: (i) restricted digestive and cerebral absorption; (ii) unnecessary peripheral distribution; (iii) short half-life; (iv) age- and PD-induced decline of central aromatic L-amino acid decarboxylase; (v) misdistribution in many cells; and (vii) pulsatile stimulation of dopaminergic receptors. Current treatments only slightly ameliorate some of these problems. Conclusions: Many Pk/Pd constraints are not resolved by existing continuous dopaminergic delivery therapies. This highlights the significant gap between these treatments and the ideal of continuous dopaminergic stimulation.
Sujet(s)
Antiparkinsoniens , Lévodopa , Maladie de Parkinson , Humains , Maladie de Parkinson/traitement médicamenteux , Maladie de Parkinson/métabolisme , Lévodopa/administration et posologie , Lévodopa/pharmacocinétique , Lévodopa/pharmacologie , Antiparkinsoniens/pharmacocinétique , Antiparkinsoniens/administration et posologie , Antiparkinsoniens/pharmacologie , Agents dopaminergiques/administration et posologie , Agents dopaminergiques/pharmacocinétique , Agents dopaminergiques/pharmacologieRÉSUMÉ
Background: The serotonin (5-HT) system can manipulate the processing of exogenous L-DOPA in the DA-denervated striatum, resulting in the modulation of L-DOPA-induced dyskinesia (LID). Objective: To characterize the effects of the serotonin precursor 5-hydroxy-tryptophan (5-HTP) or the serotonin transporter (SERT) inhibitor, Citalopram on L-DOPA-induced behavior, neurochemical signals, and underlying protein expressions in an animal model of Parkinson's disease. Methods: MitoPark (MP) mice at 20 weeks of age, subjected to a 14-day administration of L-DOPA/Carbidopa, displayed dyskinesia, referred to as LID. Subsequent investigations explored the effects of 5-HT-modifying agents, such as 5-HTP and Citalopram, on abnormal involuntary movements (AIMs), locomotor activity, neurochemical signals, serotonin transporter activity, and protein expression in the DA-denervated striatum of LID MP mice. Results: 5-HTP exhibited duration-dependent suppressive effects on developing and established LID, especially related to abnormal limb movements observed in L-DOPA-primed MP mice. However, Citalopram, predominantly suppressed abnormal axial movement induced by L-DOPA in LID MP mice. We demonstrated that 5-HTP could decrease L-DOPA-upregulation of DA turnover rates while concurrently upregulating 5-HT metabolism. Additionally, 5-HTP was shown to reduce the expressions of p-ERK and p-DARPP-32 in the striatum of LID MP mice. The effect of Citalopram in alleviating LID development may be attributed to downregulation of SERT activity in the dorsal striatum of LID MP mice. Conclusions: While both single injection of 5-HTP and Citalopram effectively mitigated the development of LID, the difference in mitigation of AIM subtypes may be linked to the unique effects of these two serotonergic agents on L-DOPA-derived DA and 5-HT metabolism.
Sujet(s)
Citalopram , Modèles animaux de maladie humaine , Dopamine , Dyskinésie due aux médicaments , Lévodopa , Sérotonine , Animaux , Lévodopa/pharmacologie , Lévodopa/effets indésirables , Dyskinésie due aux médicaments/métabolisme , Dyskinésie due aux médicaments/étiologie , Dyskinésie due aux médicaments/traitement médicamenteux , Souris , Dopamine/métabolisme , Citalopram/pharmacologie , Sérotonine/métabolisme , Transporteurs de la sérotonine/métabolisme , 5-Hydroxytryptophane/pharmacologie , Corps strié/métabolisme , Corps strié/effets des médicaments et des substances chimiques , Mâle , Inbiteurs sélectifs de la recapture de la sérotonine/pharmacologie , Carbidopa/pharmacologie , Antiparkinsoniens/pharmacologie , Antiparkinsoniens/effets indésirables , Maladie de Parkinson/métabolisme , Maladie de Parkinson/traitement médicamenteuxRÉSUMÉ
Sub-anesthetic ketamine treatment has been shown to be an effective therapy for treatment-resistant depression and chronic pain. Our group has previously shown that sub-anesthetic ketamine produces acute anti-parkinsonian, and acute anti-dyskinetic effects in preclinical models of Parkinson's disease (PD). Ketamine is a multifunctional drug and exerts effects through blockade of N-methyl-d-aspartate receptors but also through interaction with the opioid system. In this report, we provide detailed pharmacokinetic rodent data on ketamine and its main metabolites following an intraperitoneal injection, and second, we explore the pharmacodynamic properties of ketamine in a rodent PD model with respect to the opioid system, using naloxone, a pan-opioid receptor antagonist, in unilateral 6-hydroxydopamine-lesioned male rats, treated with 6 mg/kg levodopa (l-DOPA) to establish a model of l-DOPA-induced dyskinesia (LID). As previously reported, we showed that ketamine (20 mg/kg) is highly efficacious in reducing LID and now report that the magnitude of this effect is resistant to naloxone (3 and 5 mg/kg). The higher naloxone dose of 5 mg/kg, however, led to an extension of the time-course of the LID, indicating that opioid receptor activation, while not a prerequisite for the anti-dyskinetic effects of ketamine, still exerts an acute modulatory effect. In contrast to the mild modulatory effect on LID, we found that naloxone added to the anti-parkinsonian activity of ketamine, further reducing the akinetic phenotype. In conclusion, our data show opioid receptor blockade differentially modulates the acute anti-parkinsonian and anti-dyskinetic actions of ketamine, providing novel mechanistic information to support repurposing ketamine for individuals with LID.
Sujet(s)
Antiparkinsoniens , Dyskinésie due aux médicaments , Kétamine , Lévodopa , Antagonistes narcotiques , Oxidopamine , Kétamine/pharmacologie , Animaux , Mâle , Dyskinésie due aux médicaments/traitement médicamenteux , Rats , Lévodopa/pharmacologie , Antiparkinsoniens/pharmacologie , Antagonistes narcotiques/pharmacologie , Oxidopamine/toxicité , Naloxone/pharmacologie , Rat Sprague-Dawley , Modèles animaux de maladie humaineRÉSUMÉ
INTRODUCTION: Semantic fluency is the ability to name items from a given category within a limited time, which relies on semantic knowledge, working memory, and executive function. Similar to patients with Parkinson's disease (PD), patients with progressive supranuclear palsy (PSP) scored lower than healthy adults in the well-established semantic fluency test. However, it is unclear how unique are the produced words. This study examined the relationship between semantic fluency and words' uniqueness in patients with PSP. METHODS: Twenty-seven patients with PSP Richardson's syndrome (PSP-RS), 37 patients with PD, and 41 healthy controls (HC) performed a standard semantic fluency test (animals), and their verbal responses were audio-recorded. We used the uniqueness to reflect the ability to produce both original and effective work, that is, creativity. RESULTS: The PSP-RS group produced fewer correct words and fewer unique words than the PD and HC groups. Moreover, the correlation between fluency and uniqueness was positive in the HC and PD groups but negative in the PSP-RS group. Importantly, the actual levodopa dose was positively correlated with the fluency but negatively correlated with the uniqueness in PSP-RS. The PSP-RS patients who took a greater dose of levodopa tended to produce more correct words but fewer unique words. CONCLUSIONS: These results suggested that levodopa may modulate semantic fluency and uniqueness in the early stages of PSP-RS.
Sujet(s)
Lévodopa , Maladie de Parkinson , Sémantique , Paralysie supranucléaire progressive , Humains , Paralysie supranucléaire progressive/traitement médicamenteux , Paralysie supranucléaire progressive/physiopathologie , Mâle , Femelle , Sujet âgé , Lévodopa/administration et posologie , Lévodopa/pharmacologie , Lévodopa/usage thérapeutique , Maladie de Parkinson/traitement médicamenteux , Maladie de Parkinson/physiopathologie , Adulte d'âge moyen , Tests neuropsychologiques , Antiparkinsoniens/administration et posologie , Antiparkinsoniens/usage thérapeutique , Antiparkinsoniens/pharmacologieRÉSUMÉ
Parkinson's disease is caused by a selective vulnerability and cell loss of dopaminergic neurons of the Substantia Nigra pars compacta and, consequently, striatal dopamine depletion. In Parkinson's disease therapy, dopamine loss is counteracted by the administration of L-DOPA, which is initially effective in ameliorating motor symptoms, but over time leads to a burdening side effect of uncontrollable jerky movements, termed L-DOPA-induced dyskinesia. To date, no efficient treatment for dyskinesia exists. The dopaminergic and serotonergic systems are intrinsically linked, and in recent years, a role has been established for pre-synaptic 5-HT1a/b receptors in L-DOPA-induced dyskinesia. We hypothesized that post-synaptic serotonin receptors may have a role and investigated the effect of modulation of 5-HT4 receptor on motor symptoms and L-DOPA-induced dyskinesia in the unilateral 6-OHDA mouse model of Parkinson's disease. Administration of RS 67333, a 5-HT4 receptor partial agonist, reduces L-DOPA-induced dyskinesia without altering L-DOPA's pro-kinetic effect. In the dorsolateral striatum, we find 5-HT4 receptor to be predominantly expressed in D2R-containing medium spiny neurons, and its expression is altered by dopamine depletion and L-DOPA treatment. We further show that 5-HT4 receptor agonism not only reduces L-DOPA-induced dyskinesia, but also enhances the activation of the cAMP-PKA pathway in striatopallidal medium spiny neurons. Taken together, our findings suggest that agonism of the post-synaptic serotonin receptor 5-HT4 may be a novel therapeutic approach to reduce L-DOPA-induced dyskinesia.
Sujet(s)
Dyskinésie due aux médicaments , Lévodopa , Oxidopamine , Animaux , Dyskinésie due aux médicaments/traitement médicamenteux , Dyskinésie due aux médicaments/métabolisme , Lévodopa/pharmacologie , Oxidopamine/toxicité , Souris , Mâle , Souris de lignée C57BL , Agonistes des récepteurs 5-HT4 de la sérotonine/pharmacologie , Antiparkinsoniens/pharmacologie , Corps strié/effets des médicaments et des substances chimiques , Corps strié/métabolisme , Récepteurs de la sérotonine de type 5-HT4/métabolisme , Syndromes parkinsoniens/traitement médicamenteux , Syndromes parkinsoniens/métabolisme , Syndromes parkinsoniens/induit chimiquement , Pyridines/pharmacologie , Neurones/effets des médicaments et des substances chimiques , Neurones/métabolisme , Neurones/anatomopathologie , Pipéridines , PyrimidinesRÉSUMÉ
BACKGROUND: The gut microbiota has been implicated in Parkinson's disease (PD), with alterations observed in microbial composition and reduced microbial species richness, which may influence gastrointestinal symptoms in PD patients. It remains to be determined whether the severity of gastrointestinal symptoms correlates with microbiota variations in PD patients treated pharmacologically or with subthalamic nucleus deep brain stimulation (STN-DBS) therapy. This study aims to explore how these treatments affect gut microbiota and gastrointestinal symptoms in PD, identifying specific microbial differences associated with each treatment modality. METHODS: A total of 42 individuals diagnosed with PD, along with 38 age-matched household control participants, contributed stool samples for microbiota characterization. Differences in the gut microbiota across various groups of PD patients and their households were identified through comprehensive sequencing of the 16S rRNA gene amplicon sequencing. KEY RESULTS: Differences in microbial communities were observed between PD patients and controls, as well as between PD patients receiving pharmacological treatment and those with STN-DBS. Pharmacologically treated advanced PD patients have higher gastrointestinal dysfunctions. Gut microbiota profile linked to STN-DBS and reduced levodopa consumption, characterized by its anti-inflammatory properties, might play a role in diminishing gastrointestinal dysfunction relative to only pharmacological treatments. CONCLUSIONS & INFERENCES: Advanced PD patients on medication exhibit more gastrointestinal issues, despite relatively stable microbial diversity, indicating a complex interaction between gut microbiota, PD progression, and treatment effects. An imbalanced gut-brain axis, particularly due to reduced butyrate production, may lead to constipation by affecting the enteric nervous system, which emphasizes the need to incorporate gut microbiome insights into treatment strategies.
Sujet(s)
Stimulation cérébrale profonde , Microbiome gastro-intestinal , Maladie de Parkinson , Humains , Maladie de Parkinson/microbiologie , Maladie de Parkinson/thérapie , Microbiome gastro-intestinal/effets des médicaments et des substances chimiques , Microbiome gastro-intestinal/physiologie , Mâle , Femelle , Adulte d'âge moyen , Sujet âgé , Antiparkinsoniens/usage thérapeutique , Lévodopa/usage thérapeutique , Lévodopa/pharmacologie , Maladies gastro-intestinales/microbiologie , Noyau subthalamiqueRÉSUMÉ
In rodents with unilateral ablation of neurons supplying dopamine to the striatum, chronic treatment with the dopamine precursor L-DOPA induces a progressive increase of behavioral responses, a process known as behavioral sensitization. This sensitization is blunted in arrestin-3 knockout mice. Using virus-mediated gene delivery to the dopamine-depleted striatum of these mice, we find that the restoration of arrestin-3 fully rescues behavioral sensitization, whereas its mutant defective in c-Jun N-terminal kinase (JNK) activation does not. A 25-residue arrestin-3-derived peptide that facilitates JNK3 activation in cells, expressed ubiquitously or selectively in direct pathway striatal neurons, also fully rescues sensitization, whereas an inactive homologous arrestin-2-derived peptide does not. Behavioral rescue is accompanied by the restoration of JNK3 activity, as reflected by JNK-dependent phosphorylation of the transcription factor c-Jun in the dopamine-depleted striatum. Thus, arrestin-3-assisted JNK3 activation in direct pathway neurons is a critical element of the molecular mechanism underlying sensitization upon dopamine depletion and chronic L-DOPA treatment.
Sujet(s)
Arrestines , Comportement animal , Dopamine , Souris knockout , Mitogen-Activated Protein Kinase 10 , Animaux , Humains , Souris , Arrestines/métabolisme , Arrestines/génétique , Comportement animal/effets des médicaments et des substances chimiques , Corps strié/métabolisme , Corps strié/effets des médicaments et des substances chimiques , Dopamine/métabolisme , Neurones dopaminergiques/métabolisme , Neurones dopaminergiques/effets des médicaments et des substances chimiques , Activation enzymatique/effets des médicaments et des substances chimiques , Lévodopa/pharmacologie , Souris de lignée C57BL , Mitogen-Activated Protein Kinase 10/métabolisme , Mitogen-Activated Protein Kinase 10/génétique , Phosphorylation/effets des médicaments et des substances chimiquesRÉSUMÉ
Following reports of low striatal dopamine content in Parkinson's disease, levodopa was shown to rapidly reverse hypokinesis, establishing the model of disease as one of dopamine deficiency. Dopaminergic therapy became standard of care, yet it failed to reverse the disease, suggesting the understanding of disease was incomplete. The literature suggests the potential for toxicity of dopamine and its metabolites, perhaps more relevant given the recent evidence for elevated cytosolic dopamine levels in the dopaminergic neurons of people with Parkinson's. To understand the relevance of these data, multiple investigations are reviewed that tested dopamine reduction therapy as an alternative to dopaminergic agents. The data from use of an inhibitor of dopamine synthesis in experimental models suggest that such an approach could reverse disease pathology, which suggests that cytosolic dopamine excess is a primary driver of disease. These data support clinical investigation of dopamine reduction therapy for Parkinson's disease. Doing so will determine whether these experimental models are predictive and this treatment strategy is worth pursuing further. If clinical data are positive, it could warrant reconsideration of our disease model and treatment strategies, including a shift from dopaminergic to dopamine reduction treatment of the disease.